Novo Nordisk announces changes in Executive Management
Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following…
Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults…
Ozempic (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
Ozempic® improved maximum walking distance by 13% vs placebo in adults with…
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual…